NephroQuiz: a fishy rash.

NephroQuiz is curated by BMC Nephrology Editorial Board Members from Johns Hopkins University, Dr. Hanouneh and Dr. Cervantes. It aims to engage readers with clinical vignettes and problem solving. The USMLE-style questions are designed to test knowledge and engage with published literature.
NephroQuiz: a fishy rash.
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

A 51-year-old man presented for evaluation of a newly developed rash (xerosis with hyperpigmented scaly lesions on his arms, legs, abdomen, and back). Skin biopsy showed hyperkeratosis with non-necrotising granulomas. He had no medical history, did not report any nausea, vomiting, chest pain, dyspnea, or urinary symptoms. On examination his blood pressure was 125/75 mmHg, pulse rate was 85 beats per minute, and his oxygen saturation was 96%.  

Laboratory investigations showed creatinine 6.27 mg/dL (normal range 0.67–1.17; a baseline measurement 2 months before he presented was 0.9), sodium 137 mmol/L (normal range 136–145), potassium 3.8 mmol/L (normal range 3.5–5.1), bicarbonate 22 mmol/L (normal range 22–29), calcium 15.1 mg/dL (normal range 8.6–10.2), albumin 4.3 g/dL (normal range 3.5–5.2), ionized calcium 1.91 mmol/L (normal range 1.17–1.38), parathyroid hormone (PTH) 9.1 pg/mL (normal range 18.4–80.1), PTH-related protein 3.4 pmol/L (normal range 0.0–2.3), 1,25-dihydroxyvitamin D 97.3 pg/mL (normal range 19.9–79.3), and angiotensin-converting enzyme 120 U/L (normal range 16–85).

Urinalysis was positive for proteinuria with a urine protein-to-creatinine ratio of 0.92. Further serology workup showed the following: negative hepatitis B virus, hepatitis C virus, and HIV serologies, normal C3 and C4, undetectable antinuclear antibodies (ANAs), anti-double stranded DNA antibodies titer of <1:10 (normal <1:10), negative antineutrophil cytoplasmic antibodies (ANCAs), serine protease 3 antibodies (PR3-ANCAs) titer of 0 AU/mL (normal 0–19), myeloperoxidase antibodies (MPO) titer of 0 AU/mL (normal 0–19), and phospholipase A2 receptor (PLA2R) antibody titer of <1:10 (normal <1:10).

Kidney biopsy (shown above) was performed with: light microscopy hematoxylin and eosin stain (A), light microscopy periodic acid methenamine silver stain (B), IgG Immunofluorescence microscopy (C), electron microscopy (D). 

The correct answer and explanation will be revealed once you select an answer in the multiple choice question above. 

Click here to read the original case report. We encourage discussion of the case and questions in the comments. 

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Nephrology
Life Sciences > Health Sciences > Clinical Medicine > Nephrology
  • BMC Nephrology BMC Nephrology

    This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

Related Collections

With collections, you can get published faster and increase your visibility.

Immune system regulation in the kidneys

BMC Nephrology invites submissions to our Collection on Immune system regulation in the kidneys. Immune system regulation can play an important role in kidney function, with intricate mechanisms governing the interaction between the renal system and immune cells. Understanding the modulation and regulation of the immune system within the kidneys is essential for comprehending the pathophysiology of renal inflammation and immune-mediated kidney diseases. Research in this area encompasses the study of immune cell populations, immunosuppressive functions, and the maintenance of immune homeostasis within the renal microenvironment. Advancing our collective understanding of immune system regulation in the kidneys is vital for identifying the underlying mechanisms of renal inflammation and immune-mediated kidney diseases. Recent advances have revealed the pivotal role of regulatory immune cells in maintaining immune homeostasis and preventing excessive immune activation within the kidneys. Furthermore, studies have highlighted the complex interplay between immune cells and renal cells, shedding light on the mechanisms of immune-mediated kidney injury and potential targets for therapeutic intervention. Looking ahead, continued research in this area holds the potential for uncovering novel immunomodulatory pathways and therapeutic targets for immune-mediated kidney diseases. Future advances may include the development of targeted immunotherapies aimed at restoring immune homeostasis within the inflamed kidney microenvironment, as well as the identification of biomarkers for early detection and monitoring of immune-mediated kidney diseases. Topics of interest include, but are not limited to: - Immune cell populations in the kidneys - Immunomodulatory mechanisms in renal inflammation - Regulatory T cells and immune homeostasis in the kidneys - Immune-mediated kidney diseases - Role of dendritic cells in renal immune regulation - The impact of gut microbiota on renal immune responses - Novel immunotherapies for immune-mediated kidney diseases - Crosstalk between innate and adaptive immune cells in renal inflammation - The influence of aging on immune regulation in the kidneys This Collection supports and amplifies research related to SDG 3: Good Health and Wellbeing.

Publishing Model: Open Access

Deadline: Mar 17, 2025

Advances in acute kidney injury

For this Collection, BMC Nephrology is looking for contributions that discuss the latest insights, innovations, and technological advancements, with a focus on biomarkers for early detection, public awareness and policy implications, innovative therapeutic approaches, renal replacement therapy, and risk factors and prevention strategies.

Publishing Model: Open Access

Deadline: Jan 03, 2025